Edition:
United States

People: Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

81.44USD
1:12pm EDT
Change (% chg)

$0.40 (+0.49%)
Prev Close
$81.05
Open
$81.34
Day's High
$81.85
Day's Low
$81.06
Volume
8,233,010
Avg. Vol
10,226,672
52-wk High
$120.37
52-wk Low
$77.92

Bischofberger, Norbert 

Dr. Norbert W. Bischofberger, Ph.D., is Executive Vice President of Research and Development, Chief Scientific Officer of Gilead Sciences Inc. Dr. Bischofberger joined Gilead in 1990 and has served as Executive Vice President, Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech, Inc.’s DNA Synthesis group from 1986 to 1990. He received his Ph.D. in Organic Chemistry at the Eidgenossische Technische Hochschule (ETH) in Zurich, Switzerland and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts.

Basic Compensation

Total Annual Compensation, USD 2,269,230
Restricted Stock Awards, USD 2,576,440
Long-Term Incentive Plans, USD --
All Other, USD 2,107,400
Fiscal Year Total, USD 6,953,070

Options Compensation

  Quantity Market Value
Exercisable 736,500 25,416,500.00
Unexercisable 698,500 19,189,600.00
Exercised 540,000 32,892,400.00
Name Fiscal Year Total

John Martin

18,756,000

John Milligan

8,276,700

Robin Washington

5,557,230

Kevin Young

5,394,710

Norbert Bischofberger

6,953,070

Kathleen Watson

--
As Of  30 Dec 2015